Osteoporosis Treatment and Progression of Aortic Stenosis

American Journal of Cardiology

Volumn 104, Issue 1, 2009, Pages 122-124

  Skolnick, Adam H ^a   Osranek, Martin ^a   Formica, Philip ^a   Kronzon, Itzhak ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID;

ADULT; AGE DISTRIBUTION; AGED; AORTA STENOSIS; AORTA VALVE; AORTA VALVE REPLACEMENT; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE STENOSIS; OBSERVATIONAL STUDY; OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE;

AGED, 80 AND OVER; AORTIC VALVE; AORTIC VALVE STENOSIS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DISEASE PROGRESSION; FEMALE; HEMODYNAMICS; HUMANS; MALE; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 67649381813     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.02.051     Document Type: Article

References (15)

1. Aksoy Y., Yagmur C., Tekin G.O., Yagmur J., Topal E., Kekilli E., Turhan H., Kosar F., and Yetkin E. Aortic valve calcification: association with bone mineral density and cardiovascular risk factors. Coron Artery Dis 16 (2005) 379-383
2. Rosenhek R., Binder T., Porenta G., Lang I., Christ G., Schemper M., Maurer G., and Baumgartner H. Predictors of outcome in severe asymptomatic aortic stenosis. N Engl J Med 343 (2000) 611-617
3. Strickberger S.A., Schulman S.P., and Hutchins G.M. Association of Paget's disease of bone with calcific aortic valve disease. Am J Med 82 (1987) 953-956
4. Mills W.R., Einstadter D., and Finkelhor R.S. Relation of calcium-phosphorus product to the severity of aortic stenosis in patients with normal renal function. Am J Cardiol 94 (2004) 1196-1198
5. Rajamannan N.M., Subramaniam M., Rickard D., Stock S.R., Donovan J., Springett M., Orszulak T., Fullerton D.A., Tajik A.J., Bonow R.O., and Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107 (2003) 2181-2184
6. Mohler III E.R., Gannon F., Reynolds C., Zimmerman R., Keane M.G., and Kaplan F.S. Bone formation and inflammation in cardiac valves. Circulation 103 (2001) 1522-1528
7. Tamura K., Suzuki Y., Matsushita M., Fujii H., Miyaura C., Aizawa S., and Kogo H. Prevention of aortic calcification by etidronate in the renal failure rat model. Eur J Pharmacol 558 (2007) 159-166
8. Price P.A., Faus S.A., and Williamson M.K. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21 (2001) 817-824
9. Rapoport H.S., Connolly J.M., Fulmer J., Dai N., Murti B.H., Gorman R.C., Gorman J.H., Alferiev I., and Levy R.J. Mechanisms of the in vivo inhibition of bioprosthetic porcine aortic valve cusps and aortic wall with triglycidylamine/mercaptobisphosphonates. Biomaterials 28 (2007) 690-699
10. Hashiba H., Aizawa S., Tamura K., and Kogo H. Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Ther Apher Dial 10 (2006) 59-64
11. Demer L.L., and Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 117 (2008) 2938-2948
12. Aikawa E., Nahrendorf M., Figueiredo J.L., Swirski F.K., Shtatland T., Kohler R.H., Jaffer F.A., Aikawa M., and Weissleder R. Osteogenesis associates with inflammation in early-stage atherosclerosis imaging in vivo. Circulation 116 (2007) 2841-2850
13. Shao J.S., Cheng S.L., Charlton-Kachigian N., Loewy A.P., and Towler D.A. Teriparatide inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 278 (2003) 50195-50202
14. Ono N., Nakashima K., Rittling S.R., Schipani E., Hayata T., Soma K., Denhardt D.T., Kronenberg H.M., Ezura Y., and Noda M. Osteopontin negatively regulates parathyroid hormone receptor signaling in osteoblasts. J Biol Chem 283 (2008) 19400-19409
15. Steitz S.A., Speer M.Y., McKee M.D., Liaw L., Almeida M., Yang H., and Giachelli C.M. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 161 (2002) 2035-2046